Home Articoli
Migliorare la sicurezza dei pazienti e ridurre gli sprechi: la lista dei farmaci da evitare

Less is More

Migliorare la sicurezza dei pazienti e ridurre gli sprechi: la lista dei farmaci da evitare
Antonino Cartabellotta, Corrado Iacono

Evidence 2014;6(9): e1000089 doi: 10.4470/E1000089

Pubblicato: 29 settembre 2014

Copyright: © 2014 Cartabellotta. Questo è un articolo open-access, distribuito con licenza Creative Commons Attribution, che ne consente l’utilizzo, la distribuzione e la riproduzione su qualsiasi supporto esclusivamente per fini non commerciali, a condizione di riportare sempre autore e citazione originale.

Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507

Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507

Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507

Notice: Undefined index: data_varchar in /var/www/www.evidence.it/include/functions.php on line 1507
1. Towards better patient care: drugs to avoid. Prescrire Int 2013;22: 108-111.
2. Towards better patient care: drugs to avoid in 2014. Prescrire Int 2014;23:161-5.
3. About Prescrire. How we work. Disponibile a: http://english.prescrire.org/en/82/170/0/0/About.aspx. Ultimo accesso 29 settembre 2014
4. Catumaxomab: malignant ascites: unjustified marketing authorisation. Prescrire Int 2010;19:207-9
5. Panitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer. Prescrire Int 2013;22:120
6. Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects. Prescrire Int 2009;18:161
7. Trabectedin and ovarian cancer (continued). Prescrire Int 2011;20:249-250
8. Trabectedin and ovarian cancer: statistical trickery. Prescrire Int 2011;20:93.
9. Vandetanib: too dangerous in medullary thyroid cancer. Prescrire Int 2012;21:233.
10. Vinflunine. Prescrire Int 2011;20:11-3
11. Aliskiren: new drug. Arterial hypertension: no evidence of clinical efficacy. Prescrire Int 2008;17:47-50.
12. Aliskiren + hydrochlorothiazide. Prescrire Int 2010;19:64
13. Aliskiren: negative trial data. Prescrire Int 2012;21:176.
14. Fenofibrate: altered renal function. Prescrire Int 2011;20:154-5.
15. Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. Prescrire Int 1999;8:116-20.
16. Ivabradine: new drug. Best avoided in stable angina. Prescrire Int. 2007 Apr;16(88):53-6.
17. Massé JF. Stable angina: role of ivabradine unchanged between 2006 and 2010. Prescrire Int 2010;19:264.
18. Heart failure: ivabradine is no better than optimised beta-blocker therapy. Prescrire Int 2011;20:189-90.
19. Reversible Parkinsonism linked to trimetazidine (continued). Prescrire Int 2006;15:136.
20. Trimetazidine: abnormal movements and hallucinations. Should be withdrawn from the market. Prescrire Int 2009;18:69.
21. Trimetazidine: new French pharmacovigilance data. Prescrire Int 2010;19:74.
22. Topical tacrolimus and cancer (continued). Do not use. Prescrire Int 2009;18:122.
23. Topical tacrolimus and pimecrolimus: cancer, infections. Prescrire Int 2010;19:257.
24. Topical tacrolimus: cancers. Prescrire Int 2012;21:239 .
25. Injectable promethazine: gangrene. Prescrire Int 2010;19:216-7.
26. “Dexchlorpheniramin”. In: “Martindale The Complete Drug Reference” The Pharmaceutical Press, London. Disponibile a: www.medicinescomplete.com. Ultimo accesso 29 settembre 2014.
27. Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise. Prescrire Int. 2011;20:267.
28. Linagliptin. Avoid gliptins! Prescrire Int 2013;22:36-7
29. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors. Prescrire Int 2013;22:121.
30. Orlistat: hepatitis and oxalate nephropathy. Prescrire Int 2012;21:71.
31. Orlistat without a prescription. The SPC now contains more situations where patients are advised to consult a doctor. Prescrire Int 2010;19:250.
32. Orlistat without a prescription: drug interactions, pancreatitis and kidney disorders. Prescrire Int 2010;19:125.
33. Parecoxib and fatal skin reactions: when will this drug be withdrawn from the European Union market? Prescrire Int 2010;19:203.
34. Etoricoxib: a French review of adverse effects. Prescrire Int 2014;23:45.
35. Celecoxib: still around, unfortunately. Prescrire Int 2008;17:59.
36. Ketoprofen gel: severe photosensitisation. Prescrire Int 2010;19:216.
37. Ketoprofen gels. Prescrire Int 2011;20:10.
38. Piroxicam: restriction of indications: labelling change. Only half-measures. Prescrire Int 2008;17:193.
39. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int 2011;20:145-8.
40. Denosumab and bone metastases. No better than a bisphosphonate. Prescrire Int 2012;21:204-6.
41. Strontium ranelate: too many adverse effects. Prescrire Int 2011;20:154.
42. Strontium ranelate: too many adverse effects. Prescrire Int 2012;21:72.
43. Strontium ranelate for osteoporosis in men. More dangerous than beneficial. Prescrire Int 2013;22:150.
44. Strontium: myocardial infarction. Prescrire Int 2013;22:244.
45. Chondroïtine, diacéréine, insaponifiables d’avocat et de soja. Rev Prescrire 2010;30:502-3.
46. Glucosamine allergy. Prescrire Int 2006;15:139.
47. Glucosamine plus vitamin K antagonists: bleeding. One more reason to avoid using glucosamine. Prescrire Int 2009;18:68.
48. Thiocolchicoside: convulsions? Rev Prescrire 2009;29:833.
49. Quinine and cramp: uncertainty efficacy, major risks. Prescrire Int 2000;9:154-7.
50. Domperidone: ventricular arrhythmia and sudden death (continued). Prescrire Int. 2012 Jul;21(129):183.
51. Domperidone and cardiac disorders: avoid this neuroleptic. Prescrire Int. 2013 Dec;22(144):297.
52. Prucalopride. In chronic constipation: poorly documented risks. Prescrire Int 2011;20():117-20.
53. Tibolone: cancers of the breast and endometrium. Prescrire Int 2006;15:107.
54. Tibolone and stroke. Prescrire Int 2006;15:107
55. Tibolone and breast cancer. Prescrire Int 2010;19:281.
56. Moxifloxacin: new preparation. A me-too with more cardiac risks. Prescrire Int 2002;11:168-9.
57. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions. Prescrire Int 2009;18:207.
58. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int 2009;18:206.
59. Intravenous moxifloxacin. Even more harmful than the oral form. Prescrire Int 2011;20:151.
60. Telithromycin: severe hepatitis. Prescrire Int 2006;15:139.
61. Telithromycin: QT prolongation. Prescrire Int 2007;16:71.
62. Telithromycin: visual disorders, myasthenia. Case fatalities: this macrolide has a negative risk-benefit balance; its use not justified. Prescrire Int 2008;17:66.
63. Telithromycin: visual disorders. Prescrire Int 2010;19:71.
64. Rivastigmine patches: fatal overdoses. Prescrire Int 2011;20:127.
65. Anti-Alzheimer drugs: life-threatening adverse effects. Prescrire Int 2007;16:16.
66. Drugs for Alzheimer’s disease: best avoided. No therapeutic advantage. Prescrire Int 2012;21:150.
67. Donepezil: syncope. Various cardiac disorders. Prescrire Int 2008;17:113
68. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account. Prescrire Int 2011;20:95.
69. Memantine: heart failure: harmful drug. Prescrire Int 2009;18:167.
70. Pharmacological prevention of migraine: to be considered case by case. Prescrire Int 2006;15:184-8.
71. Tolcapone: new drug. In Parkinson’s disease: unacceptable risk of severe hepatitis. Prescrire Int 2006;15:54-7.
72. Vasoconstrictor: neurological and cardiovascular adverse effects. Prescrire Int 2003;12:21.
73. Vasoconstrictive decongestants: the authorities’ dithering leaves patients in danger. Prescrire Int 2013;22:72.
74. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma. Prescrire Int 2011;20:262
75. Omalizumab: anaphylactic shock: sometimes occurs more than one hour after the injection. Prescrire Int 2008;17:22.
76. Omalizumab: cardiac adverse effects. Prescrire Int 2010;19:75.
77. Omalizumab in children: a negative risk-benefit balance in severe persistent asthma. Prescrire Int 2011;20:92
78. Omalizumab: a second look in severe persistent asthma: new adverse effects. Prescrire Int 2011;20:90-2.
79. Pirfenidone. First, do no harm. Prescrire Int 2013;22:117-9.
80. Agomelatine: new drug. Adverse effects and no proven efficacy. Prescrire Int 2009;18:241-5.
81. Agomelatine: a review of adverse effects. Prescrire Int 2013;22:70-1.
82. Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int 2006;15:168-72.
83. Duloxetine: new indication. In generalised anxiety too? No thanks! No tangible efficacy but numerous and sometimes severe adverse effects. Prescrire Int 2009;18:53.
84. Duloxetine. Also avoid its use in recurrent depression. Prescrire Int 2010;19:280.
85. Duloxetine: withdrawal syndromes. Prescrire Int 2013;22:243.
86. Venlafaxine and cardiac effects. Prescrire Int 2005;14:145.
87. Asenapine: a less effective, yet, more dangerous neuroleptic! Prescrire Int 2012;21:229-32
88. Dapoxetine. Premature ejaculation: not worth the risk. Prescrire Int 2010;19:12-4.
89. Bupropion: congenital heart defects (continued). Prescrire Int. 2012 Apr;21(126):97.
90. Varenicline and bupropion: suicide. Prescrire Int 2012;21:240.
91. Varenicline: aggression and homicidal ideation. Prescrire Int. 2012 Feb;21(124):42-3.
92. Varenicline: depression and suicide. Nicotine is a safer option. Prescrire Int 2008 Jun;17:113
93. Varenicline: myocardial infarction: nicotine replacement is a better option. Prescrire Int 2008;17:23.